Levosimendan for patients with impaired left ventricular function undergoing cardiac surgery

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Low cardiac output syndrome (LCOS) is a significant complication following cardiac surgery.
• Established treatments for LCOS often have limitations or are insufficient in refractory cases.
• The perioperative efficacy of levosimendan in LCOS post-cardiac surgery remains to be fully elucidated.

Purpose of the Study:

• To evaluate the initial clinical experience and efficacy of levosimendan in patients with LCOS after cardiac surgery.
• To assess the hemodynamic effects of levosimendan in this patient population.
• To determine the feasibility of reducing concomitant inotropic support or intra-aortic balloon pumping during levosimendan treatment.

Main Methods:

• Retrospective, uncontrolled trial involving nine patients with LCOS post-cardiac surgery.
• Patients received levosimendan due to resistance to conventional inotropic support.
• Hemodynamic parameters, including cardiac index and systemic vascular resistance index, were monitored.

Main Results:

• Levosimendan administration led to a significant increase in cardiac index (from 2.14 to 2.67 l/min/m(2) at 4 hours).
• Systemic vascular resistance index significantly decreased post-levosimendan treatment (from 2350 to 1774 dynes/s/cm(-5)/m(2) at 4 hours).
• Concomitant support (inotropes or balloon pump) could be weaned in most patients within 24 hours.

Conclusions:

• Levosimendan demonstrates promising hemodynamic effects in managing LCOS after cardiac surgery.
• The drug facilitated the reduction of other supportive therapies.
• Levosimendan may represent a valuable therapeutic option for postoperative LCOS.